ARTICLE | Company News
Amgen, Celimmune deal
March 9, 2015 7:00 AM UTC
Amgen granted Celimmune exclusive, ex-Japan rights to develop and commercialize AMG 714. Celimmune is planning Phase II trials of the human mAb against IL-15 to treat diet non-responsive celiac disease and refractory celiac disease, but declined to provide a timeline. Amgen has an exclusive option to reacquire AMG 714 after Celimmune completes additional clinical trials. The partners declined to disclose financial terms. ...